The healthcare industry is experiencing a data and technological revolution that is accelerating drug discovery and delivery to patients. Over the past 15 years, we've seen an explosion of targeted therapies — including small molecules, immunotherapies, cell-based treatments, and more — all made possible by the integration of large-scale 'omics data with clinical insights, treatment approaches, and patient outcomes. However, despite these advancements, we still have a long way to go to fully
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
ActiGraph and Hyfe Launch AI-Powered Cough Detection for Clinical Trials
What You Should Know:
- ActiGraph, the global leader in wearable digital health technology for clinical research and drug development, and Hyfe Inc., the pioneer in AI-powered cough detection technology, have announced the release of their new digital health solution for detection of coughs using the ActiGraph LEAP wearable.
- This new combined solution allows researchers to leverage Hyfe’s validated cough detection algorithms alongside ActiGraph’s industry-leading digital measures for
Read More
Amplitude Vascular Systems Secures $36M to Advance Treatment for Calcified Arterial Disease
What You Should Know:
- Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease with its novel PULSE IVL™ platform, announced today that it has completed a Series B round of financing of $36M.
- The funding will support the U.S. peripheral commercial launch as well as U.S. coronary and carotid IDE trials for the company’s Pulse Intravascular Lithotripsy™ (PIVL™) device.
Amplitude Vascular Systems
Read More
OSE Immunotherapeutics & Scienta Lab Partner to Advance AI-Driven Drug Discovery
What You Should Know:
- OSE Immunotherapeutics SA, a biotechnology company focused on developing innovative immunotherapies, and Scienta Lab, a pioneer in AI-driven precision immunology is forming a strategic collaboration to leverage the power of artificial intelligence (AI) in the fight against inflammatory diseases.
- The partnership will harness Scienta Lab's advanced AI platform, EVA, to identify predictive biomarkers of efficacy for immunotherapies. EVA is a multimodal
Read More
Lantheus to Acquire Evergreen Theragnostics to Expand Radiopharmaceutical Capabilities
What You Should Know:
- Lantheus Holdings, Inc., a radiopharmaceutical company, announced today a definitive agreement to acquire Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company.
- The all-cash transaction consists of an upfront payment of $250M and up to an additional $752.5M in potential milestone payments.
- The acquisition marks Lantheus' fifth deal since January 2024 and solidifies its position as a fully integrated
Read More
Inato Launches AI-Powered Patient Pre-Screening to Reduce Site Burden and Accelerate Enrollment
What You Should Know:
- Inato, the leading platform for clinical trial access and inclusivity, today unveiled new capabilities to help research sites efficiently pre-screen patients for trial opportunities.
- The company’s latest advancement integrates a series of artificial intelligence (AI) models into a unified agent that quickly and securely reviews patient records and assesses eligibility, transforming a
Read More
Understanding Antibody Structure: A Comprehensive Guide for Beginners
Antibodies are key components of the immune system. They act as the body's defense system against invading pathogens such as bacteria and viruses. Basically, antibodies are proteins that are formed by the immune system to protect the body from antigens, which are harmful foreign substances. Therefore, antibodies aim at the antigens wishing to destroy them by signaling immune cells. The unique characteristic of antibodies is that they have the ability to identify and remember specific organisms
Read More
PathAI Partners to Deploy First AI-Powered Biospecimen Solutions
What You Should Know:
- PathAI, a leading provider of AI-powered technology for pathology, today announced a strategic partnership with Discovery Life Sciences, a leading biospecimens and specialty lab testing company, to offer Discovery’s customers enhanced, AI-enabled digital and quantitative insights from biospecimens to better inform drug and diagnostic development.
- This collaboration marks a milestone as the first at-scale deployment of AI technologies into a leading commercial
Read More
ATOMIC-Meso Trial: A New Take Against Pleural Mesothelioma
Pleural mesothelioma is a type of an aggressive cancer that develops in the tissue that surrounds the lung cavity. It is known to be primarily caused by asbestos exposure. Asbestos was largely used as a material in products revolving construction, automobile, and insulation. It is apparently still used in the said products today in buildings and houses in the U.S. The clear disparity between its latency period, which generally takes decades, compared to its fatal ramifications and little chance
Read More
Lindus Health Raises $55M to Accelerate AI-Driven Clinical Trials
What You Should Know:
- Lindus Health, a company transforming the clinical trial landscape with its tech-first approach raises $55M in Series B funding round led by Balderton Capital, with participation from Visionaries Club and existing investors Creandum, Firstminute, and Seedcamp.
- The funding will fuel the continued development of Lindus Health's AI technology and eClinical platform, Citrus™, and support the company's mission to make clinical trials faster, more reliable,
Read More
